Starflu Dosage/Direction for Use

Oseltamivir Capsules may be taken with or without food. However, when taken with food, tolerability may be enhanced in some patients.
Standard Dosage: Treatment of Infuenza: Treatment should begin within the 1st or 2nd day of onset of symptoms of influenza.
Adults and Adolescents: The recommended oral dose for treatment of influenza in adults and adolescents ≥ 13 years is 75 mg twice daily for 5 days.
Children: Children weighing > 40 kg who are able to swallow capsules may also receive treatment with a 75mg capsule twice daily.
Standard Dosage: Prophylaxis of Influenza: The recommended oral dose of Oseltamivir for prophylaxis of influenza in adults and adolescents ≥ 13 years following close contact with an infected individual is 75 mg once daily for 10 days. Therapy should begin within 2 days of exposure. The recommended dose for prophylaxis during a community outbreak of influenza is 75 mg once daily. Safety and efficacy have been demonstrated for up to 6 weeks. The duration of protection lasts for as long as dosing is continued. Children: Children weighing > 40 kg, who are able to swallow capsules, may also receive prophylaxis with a 75 mg capsule once daily.
Special Dosage Instructions: Hepatic Impairment: No dose adjustment is required for patients with mild or moderate hepatic dysfunction in the treatment or prophylaxis of influenza. The safety and pharmacokinetics in patients with severe hepatic impairment have not been studied.
Renal Impairment: Treatment of influenza: No dose adjustment is necessary for patients with creatinine clearance above 30 mL/min. In patients with a creatinine clearance of 10-30 ml/min, it is recommended that the dose be reduced to 75 mg once daily for 5 days. No dosing recommendation is available for patients undergoing routine haemodialysis and continuous peritoneal dialysis with end stage renal disease and for patients with creatinine clearance ≤ 10mL/min.
Prophylaxis of influenza: No dose adjustment is necessary for patients with creatinine clearance >30 mL/min. In patients with creatinine clearance of 10-30 mL/min, it is recommended that the dose be reduced to 75mg of capsule every other day. No dosing recommendation is available for patients undergoing routine haemodialysis and continuous peritoneal dialysis with end stage renal disease and for patients with creatinine clearance ≤ 10mL/min.
Geriatric Patient: No dose adjustment is required for elderly patients in the treatment or prophylaxis of influenza.
Children: The safety and efficacy of oseltamivir in children under 1 year has not been established.